Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trajan Group HoldingsASX:TRJ 35 ROC (Joel Greenblatt) % is 0.84% as of Dec. 2025, which is 89% below its 10-year median of 7.59. GuruFocus rates ASX:TRJ with a GF Score™ of 35/100 and a GF Value™ of A$1.12 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 840 Medical Devices & Instruments companies, Trajan Group Holdings ranks better than 51.07% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Trajan Group Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 0.84%.
The historical rank and industry rank for Trajan Group Holdings's ROC (Joel Greenblatt) % or its related term are showing as below:
ASX:TRJ'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -42.41 Med: 7.59 Max: 14.15
Current: 4.64
During the past 5 years, Trajan Group Holdings's highest ROC (Joel Greenblatt) % was 14.15%. The lowest was -42.41%. And the median was 7.59%.
ASX:TRJ's ROC (Joel Greenblatt) % is ranked better than 51.07% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 4.145
vs ASX:TRJ: 4.64
Trajan Group Holdings's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Trajan Group Holdings (ASX:TRJ) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Trajan Group Holdings ROC (Joel Greenblatt) % Related Terms
Trajan Group Holdings ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Trajan Group Holdings's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trajan Group Holdings ROC (Joel Greenblatt) % Chart
ASX:TRJ vs ISRG, BDX, MDLN: ROC (Joel Greenblatt) % Comparison
For the Medical Instruments & Supplies subindustry, Trajan Group Holdings's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trajan Group Holdings ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trajan Group Holdings's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Trajan Group Holdings's ROC (Joel Greenblatt) % falls into.
Trajan Group Holdings ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 0.84% mean?
Trajan Group Holdings (ASX:TRJ) has a ROC (Joel Greenblatt) % of 0.84% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Trajan Group Holdings and its competitors. This is 89% below median its historical median of 7.59. According to the industry distribution chart, Trajan Group Holdings ranks #411 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 48.9%.
Is Trajan Group Holdings' ROC (Joel Greenblatt) % too high?
Trajan Group Holdings' current ROC (Joel Greenblatt) % of 0.84% is 89% below median its 10-year median of 7.59. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.15. Trajan Group Holdings' value of 0.84% is 79.7% below this industry median. Based on the distribution chart, Trajan Group Holdings ranks #411 out of 840 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Trajan Group Holdings has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trajan Group Holdings' ROC (Joel Greenblatt) % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Trajan Group Holdings ranks #411 out of 840 companies for ROC (Joel Greenblatt) %. This puts Trajan Group Holdings in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 4.15. Trajan Group Holdings' value of 0.84% is 79.7% below this benchmark. While the company's 10-year median is 7.59 vs. the industry median of 4.15, Trajan Group Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.15, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trajan Group Holdings's current ROC (Joel Greenblatt) % of 0.84% is 79.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Trajan Group Holdings and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trajan Group Holdings's current ROC (Joel Greenblatt) % is 0.84%, which is 89% below median its own 10-year median of 7.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trajan Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, Trajan Group Holdings (ASX:TRJ) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.12, compared to a current price of A$0.25 — trading 78.1% below its estimated fair value. The current ROC (Joel Greenblatt) % is 0.84%, which is 89% below median its 10-year median of 7.59 and 79.7% below the Medical Devices & Instruments industry median of 4.15. Trajan Group Holdings' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Trajan Group Holdings (ASX:TRJ), the current ROC (Joel Greenblatt) % is 0.84% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trajan Group Holdings (ASX:TRJ) Overvalued in 2026?
Based on GuruFocus' analysis, Trajan Group Holdings stock appears to be undervalued.
The current stock price of A$0.25 is trading 78.1% below its estimated GF Value™ of A$1.12.
GuruFocus considers Trajan Group Holdings to be Possible Value Trap.
Key valuation signals for ASX:TRJ:
ROC (Joel Greenblatt) %: 0.84% (89% below median its 10-year median of 7.59)
GF Value™: A$1.12 vs. price of A$0.25 (78.1% below fair value)
Industry Position: 79.7% below the Medical Devices & Instruments median (#411 of 840)
No single metric tells the full story. See the ASX:TRJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trajan Group Holdings Ltd is a developer and manufacturer of analytical and life sciences products and devices, seeking to enrich human well-being through scientific measurement. Its current portfolio of products comprises products, devices and solutions that are used in the analysis of biological, food, and environmental samples. The Group now reports in three operating segments: Components and Consumables, Capital Equipment and Disruptive Technologies. Key revenue is generated from Components and consumables, which include parts, supplies, components, and consumable products worldwide. The Group operates in Asia (Malaysia, Japan and Australia and New Zealand (ANZ)), USA and Europe, Middle East, Africa, and India (EMEA).
35GF Score
Get the complete analysis for ASX:TRJ
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TRJ has been successfully added to your 
